News story | Date: 30/04/2021

The interval between the first and second dose of the mRNA vaccines (Pfizer-BioNTech and Moderna) is being extended to up to 12 weeks for all age groups under 65 years following a recommendation from the Norwegian Institute of Public Health. This only applies to people without underlying health conditions. According to preliminary estimates from the Norwegian Institute of Public Health, people aged 18 to 44 years will be offered vaccination up to 5 weeks earlier than expected in the more conservative vaccination scenario.